A Phase 1 interventional study of BMS-986256 and Famotidine in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-21.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986256 · Drug: Famotidine
Drug: BMS-986256 · Drug: Famotidine
Specified dose on specified days
Specified dose on specified days
Also known as: Pepcid
Maximum observed plasma concentration (Cmax) of BMS-986256
Time frame: Up to 19 days
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) of BMS-986256
Time frame: Up to 19 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986256
Time frame: Up to 19 days
Incidence of Adverse Events (AEs)
Time frame: Up to 45 days
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 45 days
Incidence of clinically significant changes in clinical laboratory values: Hematology tests
Time frame: Up to 45 days
Incidence of clinically significant changes in clinical laboratory values: Chemistry tests
Time frame: Up to 45 days
Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests
Time frame: Up to 45 days
Incidence of clinically significant changes in vital signs: Body temperature
Time frame: Up to 45 days
Incidence of clinically significant changes in vital signs: Respiratory rate
Time frame: Up to 45 days
Incidence of clinically significant changes in vital signs: Blood pressure
Time frame: Up to 45 days
Incidence of clinically significant changes in vital signs: Heart rate
Time frame: Up to 45 days
Incidence of clinically significant changes in Electrocardiogram (ECG) parameters: PR interval
PR interval is the time from the onset of the P wave to the start of the QRS complex
Time frame: Up to 45 days
Incidence of clinically significant changes in ECG parameters: QRS
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Time frame: Up to 45 days
Incidence of clinically significant changes in ECG parameters: QT interval
The QT interval is the time from the start of the Q wave to the end of the T wave
Time frame: Up to 45 days
Incidence of clinically significant changes in ECG parameters: QTcF
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave
Time frame: Up to 45 days
Ratio of Cmax of BMS-986256 (with famotidine versus without famotidine)
Time frame: Up to 45 days
Ratio of AUC(0-T) of BMS-986256 (with famotidine versus without famotidine)
Time frame: Up to 45 days
Ratio of AUC(INF) of BMS-986256 (with famotidine versus without famotidine)
Time frame: Up to 45 days
Time of maximum observed plasma concentration (Tmax) of BMS-986256
Time frame: Up to 45 days
Apparent terminal plasma half-life (T-HALF) of BMS-986256
Time frame: Up to 45 days
Apparent total body clearance (CLT/F) of BMS-986256
Time frame: Up to 45 days
Apparent volume of distribution of terminal phase (Vz/F) of BMS-986256
Time frame: Up to 45 days
Ran from Jun 2021 to primary completion in Sep 2021, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimetoran